Krsnaa Diagnostics Ltd. (BSE: 543328 | NSE: KRSNAA) is one of India's fastest growing diagnostic service providers, both in radiology and pathology. The Company has announced the results for nine months ending December 31, 2021.
9M FY2022 Performance Highlights
- Revenue from operations of Rs. 347 crores, up 16% y-o-y
- EBITDA* of Rs. 105 crores, up 73% y-o-y
- EBITDA* Margins increased to 30.2% in 9M FY22 as compared to 20.2% in 9M FY21
- Profit After Tax** of Rs. 50 crores, up by 215% with margins of 14.1%
- Core business i.e. radiology and pathology registered a revenue increase of 85% y-o-y, which was partially offset by decline of 71% in Covid-19 revenues
- Core business contribution was 89% whereas Covid-19 business contributed 11% to the total revenues in 9M FY22
* EBITDA is excluding CSR and ESOP expenses ** PAT without exceptional Items
Commenting on the results, Mr. Yash Mutha, Executive Director, said: "In 9MFY22, Krsnaa Diagnostics has delivered strong performance with revenues of Rs. 347 crore, an increase of 16% y-o-y. The growth was underpinned by Core Businesses which grew by 85% and partially offset by decline of 71% in Covid-19 revenues. EBITDA stood at Rs. 105 crore, a strong growth of 73% y-o-y with margins improving significantly to 30.2% as compared to 20.2% in 9M FY21. The EBITDA margin improvement was driven by higher number of tests, contribution from our Core Businesses and operational efficiencies in the business model. Similarly, Profit after tax stood at Rs. 50 crore, a growth of 215% with PAT margins of 14.1%. Furthermore, it is encouraging to see that within the first nine months of FY2022, Krsnaa has surpassed FY21 numbers in terms EBITDA and PAT.
On the operational front, we continue to see volume growth of 81% y-o-y across all core test categories in 9M FY22.
We continued our growth momentum in Q3 FY22, with revenue of Rs. 106 crore, an increase of 8.8% y-o-y. This growth is primarily driven by Core Business of Radiology and Pathology which grew by 34% y-o-y and was partially offset by a decline of 93% y-o-y in Covid-19 revenues. If we look at the performance on a sequential basis, the company registered a nominal growth of 2% in Core Business and Profit after tax grew up by 30% on q-o-q basis. During the quarter, we continued to focus on our underlying strengths and reduce dependance on covid business, along with overall moderation visible in the industry due to festive season.
In terms of setting up new centres, the progress remains on track and by end of January 2022, we have operationalized 5 centres in Punjab and 1 centre in Mumbai for Radiology and 5 processing centres, 42 collection centres for Pathology in Punjab. There are 10 Radiology centres for which construction has already been completed and 14 centres are under construction, these centres are expected to operationalize in the coming months. We are well positioned to benefit from the commissioning on new centres and the meaningful contribution from these upcoming centres should be visible in the next fiscal year. In Q3 FY22, we have incurred a total Capex of Rs. 39 crores in setting up these facilities.
The performance during the year is a testament that Krsnaa Diagnostics has built a strong foundation to deliver consistent growth in its Core Business coupled with the operationalization of new centres, we are on our course to deliver accelerated growth in the coming years. With a well-defined growth strategy, we expect to remain one of the fastest growing diagnostic chain in India, creating value for all stakeholders and fulfilling our mission 'To make a difference in the healthcare diagnostic industry'."
Shares of Krsnaa Diagnostics Ltd was last trading in BSE at Rs. 660.90 as compared to the previous close of Rs. 676.30. The total number of shares traded during the day was 8956 in over 805 trades.
The stock hit an intraday high of Rs. 686.20 and intraday low of 656.50. The net turnover during the day was Rs. 6035576.00.
Source : Equity Bulls